Drug Trial Radar · NCT05384262
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
May 18, 2022
Primary completion
Jun 14, 2024
Study completion Jun 14, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- May 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels. This study will consist of two parts (Parts A and B). 56 subjects have been planned for Part A and 141 subjects for Part B. Additional subjects may be included for the optional cohorts depending upon emerging data.
Conditions
- Dyslipidemia
Interventions
AZD0780Drug
Subjects will receive AZD0780 orally as a single ascending dose.
AZD0780Drug
Subjects will receive AZD0780 orally as a multiple ascending dose.
AZD0780Drug
Subjects will receive AZD0780 orally as a single and multiple ascending dose.
PlaceboDrug
Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
PlaceboDrug
Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
PlaceboDrug
Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
RosuvastatinDrug
Subjects will receive rosuvastatin orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with Adverse EventsTime frame: From Screening (≤ 28 days) until Follow-up Visit (5 to 7 days post-dose for all cohorts, and 9 to 11 days post-dose for subjects from Cohort 3 onwards)
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Glendale, California
Research Site
Brooklyn, Maryland
Research Site
Harrow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.